A Phase IIb Randomised Clinical Trial of the Tolerability, Safety and Efficacy of Adjuvant Docetaxel-Zoledronic Acid After Prostatectomy for High-risk Early Prostate Cancer (AD-ZAP).
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2010
At a glance
- Drugs Docetaxel; Zoledronic acid
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AD-ZAP
- Sponsors Novartis
- 20 Apr 2010 Actual end date (Nov 2006) and actual number of patients (1) added as reported by ClinicalTrials.gov.
- 07 Dec 2006 New trial record.